Results 51 to 60 of about 14,165 (152)

Optimizing the integration of modern systemic therapies and advanced radiotherapy techniques in breast cancer management: An expert opinion from the Institut Curie Breast Radiotherapy Group

International Journal of Cancer, Volume 158, Issue 7, Page 1775-1784, 1 April 2026.
Abstract The integration of modern systemic therapies with radiotherapy (RT) represents a promising strategy in breast cancer management, enhancing both locoregional control and systemic disease outcomes. This expert consensus from the Institut Curie Breast Radiotherapy Group focuses exclusively on modern systemic agents, synthesizing current evidence ...
Cezara Cheptea, Pierre Loap, Sofiane Allali, Alain Fourquet, Kim Cao, Youlia Kirova   +5 more
wiley   +1 more source

O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer

Nature Communications
Cyclin-dependent kinases 4 and 6 (CDK4/6) play a pivotal role in cell cycle and cancer development. Targeting CDK4/6 has demonstrated promising effects against breast cancer.
Yi Zhang, Shuyan Zhou, Yan Kai, Ya-qin Zhang, Changmin Peng, Zhuqing Li, Muhammad Jameel mughal, Belmar Julie, Xiaoyan Zheng, Junfeng Ma, Cynthia X. Ma, Min Shen, Matthew D. Hall, Shunqiang Li, Wenge Zhu   +14 more
doaj   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, Volume 20, Issue 3, Page 779-803, March 2026.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand

BMC Cancer
Background The current standard first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR + /HER2 −) advanced breast cancer (ABC) is a combination of aromatase inhibitor (AI) plus CDK4/6 inhibitors (CDK4/6i).
Thanate Dajsakdipon, Thiti Susiriwatananont, Concord Wongkraisri, Suthinee Ithimakin, Napa Parinyanitikul, Archara Supavavej, Arunee Dechaphunkul, Patrapim Sunpaweravong, Sunee Neesanun, Charuwan Akewanlop, Thitiya Dejthevaporn, TSCO Breast Oncology Group   +11 more
doaj   +1 more source

Molecular Characteristics, Potential Mechanisms, and Prognostic Gene Model of Younger Female Patients With Gastric Cancer

Cancer Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background Male patients were twice as likely to develop gastric cancer (GC) compared to females, partly due to the protective effect of estrogen. However, the proportion of females increased in the young GC patients. Aims The study was designed to explore comprehensive molecular profiles of younger female GC patients, as well as develop a ...
Xiaoyi Luan, Lulu Zhao, Wanqing Wang, Penghui Niu, Xue Han, Zerong Wang, Xiaojie Zhang, Dongbing Zhao, Yingtai Chen   +8 more
wiley   +1 more source

Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination

Advances in Radiation Oncology, 2019
Purpose: Palbociclib is a selective cyclin-dependent kinase 4/6 inhibitor approved for metastatic ER+/HER2- breast cancer. Preclinical evidence suggests a possible synergistic effect of palbociclib when combined with radiation therapy (RT); however, the ...
Mudit Chowdhary, MD, Neilayan Sen, MD, Akansha Chowdhary, MD, Lydia Usha, MD, Melody A. Cobleigh, MD, Dian Wang, MD, PhD, Kirtesh R. Patel, MD, Parul N. Barry, MD, Ruta D. Rao, MD   +8 more
doaj   +1 more source

Extent and Incidence of Pseudo‐Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real‐World Data

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 802-811, March 2026.
A considerable number of oral antitumor therapeutics (OAT) has the potential for causing pseudo‐worsening of kidney function (PW) due to inhibition of renal creatinine secretion, i.e., kidney function is unaffected, while creatinine‐based calculation of glomerular filtration rate (eGFR) erroneously indicates an impaired kidney function.
Michael I. Sponfeldner, Pauline Dürr, Phyllis Lensker, Katja Gessner, Lisa Cuba, Rainer Fietkau, Markus F. Neurath, Bernd Wullich, Marianne Pavel, Carola Berking, Matthias W. Beckmann, Andreas Mackensen, Frank Dörje, Martin F. Fromm   +13 more
wiley   +1 more source

Targetable Vulnerabilities in MYC‐Driven B Cell Lymphomas Resistant to BCR Extinction

Hematological Oncology, Volume 44, Issue 2, March 2026.
ABSTRACT Polatuzumab vedotin, an antibody‐drug conjugate (ADC) targeting the B cell receptor (BCR) signaling subunit CD79B, has recently entered frontline therapy for diffuse large B cell lymphoma (DLBCL) and high‐grade B cell lymphoma (HGBCL), achieving encouraging clinical results. However, MYC‐driven B cell lymphomas, particularly HGBCL with MYC and
Silvia Brambillasca, Nicara Chantal Parr, Adriana Palmeri, Adrian Andronache, Hiroshi Arima, Giovanni Faga’, Brian Leuzzi, Laura Perucho, Michela Robusto, Maurizio Pasi, Federica Mainoldi, Daniele Fancelli, Mario Varasi, Gabriele Varano, Ciro Mercurio, Stefano Casola   +15 more
wiley   +1 more source

Local Anesthetics in Cancer: Mechanisms and Translational Perspectives

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Local anesthetics demonstrate multifaceted antitumor effects that collectively contribute to cancer suppression. Beyond canonical sodium channel blockade, these agents exert the following pharmacological actions: inhibition of tumor cell proliferation, suppression of migration and invasion, induction of proapoptotic pathways, attenuation of ...
Wan‐li Wang, Tu Huang, Yi‐hang Hao, Min Zheng, Xin‐hua Liang   +4 more
wiley   +1 more source

Aging‐Derived Alterations in Genomic, Immune, and Metabolic Networks: Implications for Cancer Development and Therapy

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Ageing acts as a double‐edged sword in cancer. In the elderly, open chromatin, immunosenescence, and chronic inflammation drive SASP (IL‐6, MMPs), MDSC accumulation and T‐cell suppression, fostering tumor‐promoting microenvironments and limited therapeutic benefit.
Qi Wang, Xue Sun, Xinhao Han, Xingda Zhang, Wenzheng Wang, Hongbin Wang, He Ren, Lina Gu   +7 more
wiley   +1 more source